DK1910521T3 - Generering af allo-begrænsede, antigenspecifikke T-celler - Google Patents

Generering af allo-begrænsede, antigenspecifikke T-celler

Info

Publication number
DK1910521T3
DK1910521T3 DK06776623.8T DK06776623T DK1910521T3 DK 1910521 T3 DK1910521 T3 DK 1910521T3 DK 06776623 T DK06776623 T DK 06776623T DK 1910521 T3 DK1910521 T3 DK 1910521T3
Authority
DK
Denmark
Prior art keywords
cells
specific
antigen
allo
generation
Prior art date
Application number
DK06776623.8T
Other languages
English (en)
Inventor
Dolores Schendel
Susanne Wilde
Thomas Blankenstein
Original Assignee
Helmholtz Zentrum Muenchen
Max Delbrueck Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen, Max Delbrueck Centrum filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of DK1910521T3 publication Critical patent/DK1910521T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK06776623.8T 2005-08-05 2006-08-04 Generering af allo-begrænsede, antigenspecifikke T-celler DK1910521T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05017128 2005-08-05
EP06007539 2006-04-10
PCT/EP2006/007752 WO2007017201A1 (en) 2005-08-05 2006-08-04 Generation of antigen specific t cells

Publications (1)

Publication Number Publication Date
DK1910521T3 true DK1910521T3 (da) 2011-02-07

Family

ID=37598202

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06776623.8T DK1910521T3 (da) 2005-08-05 2006-08-04 Generering af allo-begrænsede, antigenspecifikke T-celler
DK10179257.0T DK2327763T3 (da) 2005-08-05 2006-08-04 Antigen generation af specifikke T-celler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10179257.0T DK2327763T3 (da) 2005-08-05 2006-08-04 Antigen generation af specifikke T-celler

Country Status (11)

Country Link
US (2) US8486694B2 (da)
EP (3) EP3369812B1 (da)
JP (3) JP5079697B2 (da)
AT (1) ATE484578T1 (da)
DE (1) DE602006017556D1 (da)
DK (2) DK1910521T3 (da)
ES (2) ES2842878T3 (da)
HU (1) HUE038833T2 (da)
PL (1) PL2327763T3 (da)
PT (1) PT2327763T (da)
WO (1) WO2007017201A1 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
CA2751762A1 (en) * 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit U Nd Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
AU2011304728A1 (en) * 2010-09-20 2013-03-14 Biontech Ag Antigen-specific T cell receptors and T cell epitopes
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CA3114877C (en) * 2011-09-15 2023-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
IL288241B2 (en) * 2012-06-11 2023-10-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
HK1212237A1 (en) 2012-08-31 2016-06-10 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3071686B1 (en) * 2013-11-22 2020-07-22 Cellectis SA Method for generating batches of allogeneic t-cells with averaged potency
MX374472B (es) 2014-03-20 2025-03-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
EP3137100B1 (en) * 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
KR20170075785A (ko) * 2014-11-05 2017-07-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
ES2784261T3 (es) * 2014-11-26 2020-09-23 Us Health Receptores de células T anti-KRAS mutado
AU2016232280B2 (en) * 2015-03-16 2018-05-31 Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
GB2557123B (en) 2015-07-31 2021-11-03 Univ Minnesota Modified cells and methods of therapy
ES2879287T3 (es) * 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
BR112018012694A2 (pt) 2015-12-23 2018-12-04 Medigene Immunotherapies Gmbh composição de célula dendrítica, vacina de célula dendrítica, composição e kit
ES2964746T3 (es) * 2015-12-30 2024-04-09 Celgene Corp Métodos de producción de linfocitos T y linfocitos T producidos mediante el mismo
EP3475706B1 (en) * 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
MX2019003176A (es) * 2016-09-23 2019-07-04 Hutchinson Fred Cancer Res Receptores de linfocitos t (tcr) especificos del antigeno menor de histocompatibilidad (h) ah-1 y sus usos.
GB2573406B (en) 2016-10-18 2021-11-10 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
TWI837109B (zh) * 2017-12-28 2024-04-01 美商磨石生物公司 靶向共有抗原之抗原結合蛋白
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
EP4424710A3 (en) 2018-02-26 2025-01-15 Medigene Immunotherapies GmbH Nyeso tcr
KR20210049119A (ko) * 2018-08-22 2021-05-04 프레드 헛친슨 켄서 리서치 센터 Kras 또는 her2 항원을 표적으로 하는 면역요법
EP3849569A4 (en) * 2018-09-10 2022-06-08 Torque Therapeutics, Inc. ANTIGEN-SPECIFIC T LYMPHOCYTES AND METHODS OF MAKING AND USING THEM
WO2020069452A1 (en) * 2018-09-27 2020-04-02 Genocea Biosciences, Inc. Treatment methods
EP3894544A4 (en) * 2018-12-12 2023-03-29 The Brigham & Women's Hospital, Inc. Compositions and methods for immunosuppression
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
JP6878544B2 (ja) * 2019-10-02 2021-05-26 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
JP7340144B2 (ja) * 2019-10-02 2023-09-07 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
CU20220044A7 (es) * 2020-02-12 2023-06-13 Us Health Receptor de células t restringido por hla de la clase i contra ras con mutación g12d
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
JP7518915B2 (ja) 2020-04-01 2024-07-18 メディジーン イミュノテラピーズ ゲーエムベーハー Ｃｄ３融合タンパク質およびその使用
CA3176826A1 (en) * 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2022038115A1 (en) 2020-08-18 2022-02-24 Medigene Immunotherapies Gmbh ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY
BR112023005318A2 (pt) 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh Receptores de célula t específicos de prame e uso dos mesmos
AU2021388167A1 (en) * 2020-11-25 2023-07-06 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
CA3202176A1 (en) * 2020-12-14 2022-06-23 Michael Steven ROONEY Tissue-specific antigens for cancer immunotherapy
WO2023175070A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library
WO2023175069A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library for pramevld tcrs
GB2640828A (en) * 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
DE50207025D1 (de) * 2002-08-23 2006-07-06 Deutsches Rheuma Forschungszen Verfahren zum Nachweis und zur Isolierung von T-Lymphozyten, die ein definiertes Antigen erkennen
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler

Also Published As

Publication number Publication date
ES2672895T3 (es) 2018-06-18
ES2842878T3 (es) 2021-07-15
DK2327763T3 (da) 2018-05-22
EP3369812B1 (en) 2020-10-07
JP2016135127A (ja) 2016-07-28
WO2007017201A1 (en) 2007-02-15
US8486694B2 (en) 2013-07-16
JP5079697B2 (ja) 2012-11-21
JP2009502185A (ja) 2009-01-29
US20140141026A1 (en) 2014-05-22
JP2012213402A (ja) 2012-11-08
EP1910521A1 (en) 2008-04-16
EP2327763A1 (en) 2011-06-01
DE602006017556D1 (de) 2010-11-25
US20100189728A1 (en) 2010-07-29
PL2327763T3 (pl) 2018-08-31
EP1910521B1 (en) 2010-10-13
EP3369812A1 (en) 2018-09-05
PT2327763T (pt) 2018-05-11
HUE038833T2 (hu) 2018-11-28
ATE484578T1 (de) 2010-10-15
EP2327763B1 (en) 2018-03-14

Similar Documents

Publication Publication Date Title
HUE038833T2 (hu) Antigénspecifikus T-sejtek létrehozása
Tian et al. Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection
Schatton et al. ABCB5 identifies immunoregulatory dermal cells
Pang et al. Current progress of CAR-NK therapy in cancer treatment
Galli et al. Invariant NKT cells sustain specific B cell responses and memory
EA201100663A1 (ru) Соединения, которые увеличивают количество гематопоэтических стволовых клеток
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
MX2007000210A (es) Anticuerpos que se unen a los receptores kir2dl1,-2,3 pero no a kir2ds4 y su uso terapeutico.
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
WO2005004592A3 (en) Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
CY1114755T1 (el) Ρυθμιση των τ κυτταρων
BR112014006176A8 (pt) Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada
DK1483294T3 (da) Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
Yamaki et al. OX40 and IL‐7 play synergistic roles in the homeostatic proliferation of effector memory CD4+ T cells
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
Lindqvist et al. T regulatory cells in B‐cell malignancy–tumour support or kiss of death?
Moon et al. Use of epigenetic modification to induce FOXP3 expression in naïve T cells
EP1769066A4 (en) MODIFIED ANTIGEN PRESENTING CELLS
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
Chatenoud Natural and induced T CD4+ CD25+ FOXP3+ regulatory T cells
Simpson Special regulatory T‐cell review: regulation of immune responses–examining the role of T cells
DK1788078T3 (da) Dendritisk celle-lægemiddel indeholdende den dendritiske celle, terapeutisk fremgangsmåde under anvendelse af den dendritiske celle og fremgangsmåde til dyrkning af gammadelta-T-celle
DK1572133T3 (da) Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor